Navigation Links
Isis Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/6/2011

CARLSBAD, Calif., Jan. 6, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at J.P. Morgan's 29th Annual Healthcare Conference on Thursday, January 13, 2011 at 8:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.  Additional information about Isis is available at

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
2. Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
3. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
4. Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors
5. ISTA Pharmaceuticals Achieves 2010 Revenue and Earnings Guidance; Provides 2011 Financial Guidance and Updates Key Plans
6. Omthera Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
8. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
9. Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12
10. MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... SEATTLE, March 25 Cell Therapeutics, Inc.,(CTI) (Nasdaq: ... complete in,the phase III EXTEND (PIX301) clinical trial of ... non-Hodgkin,s lymphoma (NHL).,An analysis of the data is expected ... with the U.S. Food and Drug Administration (FDA) the ...
... Patients to ... Higher Rates of BARACLUDE Resistance -, PRINCETON, N.J., ... a continued low incidence of,resistance in nucleoside-naive patients through ... patients analyzed, no additional,patient developed resistance in the fifth ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 2Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 3Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 3BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 5BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 6
(Date:7/26/2014)... European security and surveillance radar market under defense aviation ... is expected to reach $1800 million by 2019 at ... that influence a country’s expenditure on radars. It provides ... The report also throws light on the leading competitors ... of the companies, it focuses on their financial position, ...
(Date:7/26/2014)... Recently, iFitDress.com, a popular supplier of ... unveiled its new range of high quality party outfits. ... brand new items; they are now provided at discounted ... is one of the leading suppliers in the international ... wholesale party dresses have flattering looks and ...
(Date:7/26/2014)... 26, 2014 As reported by ... changing based on 3 factors: smaller spaces, multi-generational access, ... bathroom trend of 2014 lists, including this article ... Amerec , a leading manufacturer of steam bath ... largely due to smaller spaces and an effort to ...
(Date:7/26/2014)... July 26, 2014 “Healthy teeth are important, ... those pearly whites shining,” says Community Health Center of Snohomish ... ." , They believe that an integration of medical and ... and well. Because of this, they encourage regular cleanings and ... dentist . , “Children and adults will find ...
(Date:7/26/2014)... OH (PRWEB) July 26, 2014 The U.S. ... guidelines list that includes a new medication guide for AndroGel ... a serious side-effect of taking the topical low testosterone medication, ... that AbbVie Inc., the makers of the low testosterone theapy ... symptoms of pain, swelling or redness as signs of a ...
Breaking Medicine News(10 mins):Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 4Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 5Health News:High Quality Wholesale Party Dresses Online at iFitDress.com 2Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5
... , ORANGE COUNTY, Calif., Oct. 14 Beckman Coulter, Inc. ... conference call on Thursday, October 29, 2009, at 5:00 p.m. ... Earnings will be released after the market closes. , (Logo: ... by dialing (877) 516-3365 or (706) 679-3246 and asking for ...
... American Academy of Physician Assistants (AAPA), representing 75,000 ... States, applauds the Senate Finance Committee,s vote to ... is committed to seeking health care reform legislation ... quality, affordable, cost-effective health care. , "Physician ...
... Payment Would Cover Just Two Percent of Lost Income ... Security Administration is expected to announce that seniors will receive ... checks next year. , President Obama,s call late this ... for seniors would make up just a tiny fraction of ...
... Inc. magazine ranked Texas Physical Therapy Specialists ... an exclusive ranking of the nation,s fastest-growing private companies. The ... segment of the economy--America,s independent-minded entrepreneurs. , "If you want ... look at the Inc. 500," said Inc. editor Jane Berentson. ...
... received artificial kidney treatment: study , WEDNESDAY, Oct. 14 (HealthDay ... older Americans in nursing homes who suffer kidney failure in ... published in the Oct. 15 issue of the New ... to lengthen or improve most patients, lives. , "The hope ...
... ... and CEO of Atlanta-based Jackson Healthcare, proposed a radical plan to ... stage as the current administration spearheads an aggressive reform of the ... propaganda that have saturated the news, Jackson’s core argument remains as ...
Cached Medicine News:Health News:American Academy of Physician Assistants Applauds Senate Finance Committee for Advancing Health Reform Legislation 2Health News:Social Security COLA: Tomorrow's Zero COLA Announcement for 2010 Could Cost Average Senior $10,134 2Health News:Inc. Magazine Unveils 28th Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:Dialysis' Drawbacks Outweigh Benefits for Some Older Patients 2Health News:Dialysis' Drawbacks Outweigh Benefits for Some Older Patients 3Health News:Restoring the Physician/Patient Relationship: An Interview with Jackson Healthcare's CEO 2Health News:Restoring the Physician/Patient Relationship: An Interview with Jackson Healthcare's CEO 3Health News:Restoring the Physician/Patient Relationship: An Interview with Jackson Healthcare's CEO 4Health News:Restoring the Physician/Patient Relationship: An Interview with Jackson Healthcare's CEO 5
... VICTOR2 V ... fluorescence polarization, luminescence, ... and absorbance. A ... LANCE assay. All ...
This is the modular VICTOR2 multilabel counter with the TR-fluorometry, stacker and robot loading options.The addition of a xenon flash lamp brings the time-resolved fluorescence counting mode to th...
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... readers available today operate with either one, ... speed) or use an imaging process to ... sensitivity and the individual signals can overlap). ... miniature lens array containing 96 parallel micro-objectives. ...
Medicine Products: